PTIX

Protagenic Therapeutics, Inc. [PTIX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PTIX Stock Summary

Top 10 Correlated ETFs

PTIX


Top 10 Correlated Stocks

PTIX


In the News

05:00 29 Mar 2024 PTIX

Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day.

09:00 29 Mar 2024 PTIX

Protagenic Therapeutics Announces Date of Annual Shareholder Meeting

NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th. Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/PTIX2023.

08:15 29 Mar 2024 PTIX

Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th

NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022.

05:17 29 Mar 2024 PTIX

Protagenic Therapeutics Shares Increase Over 10% Pre-Market: Why It Happened

The shares of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 10% pre-market. This is why it happened.

06:31 29 Mar 2024 PTIX

Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End

Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application sought approval to start a Phase 1/2a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, anxiety, and depression.

06:17 29 Mar 2024 PTIX

Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction on Tuesday, July 13 at 10:00AM ET.

02:19 29 Mar 2024 PTIX

7 Best Penny Stocks to Buy Now for Potential 10X Gains

Penny stocks offer a lot of risk balanced by lots of reward. Here are 7 that could surge in price and which have reasonable catalysts behind them.

08:38 29 Mar 2024 PTIX

PTIX Stock Price: Over 25% Increase Pre-Market Explanation

The stock price of Protagenic Therapeutics Inc (NASDAQ: PTIX) increased by over 25% pre-market. These are the details.

09:04 29 Mar 2024 PTIX

Best Biotech Penny Stocks in June 2021? Check These 4 Out

Looking for biotech penny stocks for your June watchlist? Here's 4 to watch The post Best Biotech Penny Stocks in June 2021?

02:25 29 Mar 2024 PTIX

4 Biotech Penny Stocks That You Need to Know About

These biotech penny stocks pushed up big today; but are they worth it? The post 4 Biotech Penny Stocks That You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PTIX Financial details

Company Rating
Sell
Market Cap
6.87M
Income
-3.94M
Revenue
0
Book val./share
0.96
Cash/share
1.22
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
17 Apr 2024
P/E
-0.95
Forward P/E
-0.72
PEG
0.29
P/S
-
P/B
0.9
P/C
1.49
P/FCF
-1.39
Quick Ratio
4.12
Current Ratio
4.2
Debt / Equity
0.1
LT Debt / Equity
-
-
-
EPS (TTM)
-0.91
EPS next Y
-2.52
EPS next Q
1.58
EPS this Y
-38.52%
EPS next Y
176.92%
EPS next 5Y
176.92%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
14.29%
-
-
-
-
SMA20
55.79%
SMA50
68.18%
SMA100
85%
Inst Own
0%
Inst Trans
0%
ROA
-73%
ROE
-69%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
4.44M
Shs Float
3.55M
-
-
-
-
Target Price
-
52W Range
0.68-2.32
52W High
-
52W Low
-
RSI
81.03
Rel Volume
3.64
Avg Volume
8.98K
Volume
32.67K
Perf Week
51.67%
Perf Month
87.63%
Perf Quarter
51.7%
Perf Half Y
3.41%
-
-
-
-
Beta
0.296
-
-
Volatility
0.19%, 0.26%
Prev Close
4%
Price
1.82
Change
8.98%

PTIX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1-0.69-1.08-1.35-0.83
Operating cash flow per share
-0.42-0.19-0.52-0.76-0.46
Free cash flow per share
-0.42-0.19-0.52-0.76-0.46
Cash per share
0.240.310.262.811.85
Book value per share
-0.08-0.25-0.442.71.6
Tangible book value per share
-0.08-0.25-0.442.71.6
Share holders equity per share
-0.08-0.25-0.442.71.6
Interest debt per share
00.120.630.220.11
Market cap
5.13M3.62M2.71M20.42M6.91M
Enterprise value
4.77M3.1M3.42M20.19M7.04M
P/E ratio
-2.01-2.05-0.97-4.09-1.92
Price to sales ratio
00000
POCF ratio
-4.79-7.41-2.01-7.3-3.47
PFCF ratio
-4.79-7.41-2.01-7.3-3.46
P/B Ratio
-24.33-5.7-2.362.051
PTB ratio
-24.33-5.7-2.362.051
EV to sales
00000
Enterprise value over EBITDA
-2.31-1.49-1.34-4.92-2.09
EV to operating cash flow
-4.45-6.35-2.53-7.22-3.53
EV to free cash flow
-4.45-6.35-2.53-7.22-3.53
Earnings yield
-0.5-0.49-1.03-0.24-0.52
Free cash flow yield
-0.21-0.13-0.5-0.14-0.29
Debt to equity
0-0.44-1.190.030.05
Debt to assets
00.331.560.030.04
Net debt to EBITDA
0.180.25-0.280.05-0.04
Current ratio
0.770.71.3413.837.18
Interest coverage
-829.44-131.32-10.36-8.33-25.88
Income quality
0.420.280.530.620.56
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0000-60.17
Stock based compensation to revenue
00000
Graham number
1.361.963.299.065.48
ROIC
13.065.93-12.49-0.44-0.5
Return on tangible assets
-3.67-2.1-3.18-0.45-0.45
Graham Net
-0.11-0.26-0.532.511.59
Working capital
-211.49K-355.29K224.06K10.26M6.92M
Tangible asset value
-210.88K-634.37K-1.15M9.94M6.92M
Net current asset value
-211.49K-634.66K-1.15M9.94M6.92M
Invested capital
0-0.44-1.190.030.05
Average receivables
00000
Average payables
26.26K44.26K89.01K210.4K474.33K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
038.93K181.05K08.15M
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00.01000
Inventory turnover
00000
ROE
12.132.792.43-0.5-0.52
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.21-0.14-0.17-0.28-0.32
Operating cash flow per share
-0.12-0.04-0.09-0.35-0.15
Free cash flow per share
-0.12-0.04-0.09-0.35-0.16
Cash per share
1.891.851.771.41.22
Book value per share
1.711.61.491.250.96
Tangible book value per share
1.711.61.491.250.96
Share holders equity per share
1.711.61.491.250.96
Interest debt per share
0.080.090.090.10.1
Market cap
9.85M6.91M7.47M8.79M7.97M
Enterprise value
10.01M7.04M7.7M8.97M8.24M
P/E ratio
-2.75-2.84-2.56-1.82-1.43
Price to sales ratio
00000
POCF ratio
-18.41-38.18-20.09-5.74-12.15
PFCF ratio
-18.41-37.81-20.09-5.74-11.2
P/B Ratio
1.3311.161.621.92
PTB ratio
1.3311.161.621.92
EV to sales
00000
Enterprise value over EBITDA
-11.36-12.49-11.29-8.47-6.15
EV to operating cash flow
-18.71-38.9-20.71-5.85-12.56
EV to free cash flow
-18.71-38.51-20.71-5.85-11.57
Earnings yield
-0.09-0.09-0.1-0.14-0.18
Free cash flow yield
-0.05-0.03-0.05-0.17-0.09
Debt to equity
0.040.050.060.070.1
Debt to assets
0.040.040.050.060.08
Net debt to EBITDA
-0.18-0.23-0.34-0.17-0.2
Current ratio
14.917.186.124.64.2
Interest coverage
-28.92-20.52-23.65-36.18-44.8
Income quality
0.580.30.521.270.47
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000.09
Capex to revenue
00000
Capex to depreciation
0-60.1700-39.33
Stock based compensation to revenue
00000
Graham number
2.822.252.372.82.64
ROIC
-0.12-0.09-0.11-0.2-0.33
Return on tangible assets
-0.11-0.08-0.09-0.17-0.26
Graham Net
1.681.591.481.050.92
Working capital
7.7M6.92M6.41M5.41M4.1M
Tangible asset value
7.38M6.92M6.41M5.41M4.15M
Net current asset value
7.38M6.92M6.41M5.41M4.1M
Invested capital
0.040.050.060.070.1
Average receivables
00000
Average payables
236.82K404.52K422.29K166.52K200.85K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
02.01M174.87K156.43K15.45K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000.01
Inventory turnover
00000
ROE
-0.12-0.09-0.11-0.22-0.34
Capex per share
0000-0.01

PTIX Frequently Asked Questions

What is Protagenic Therapeutics, Inc. stock symbol ?

Protagenic Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol PTIX

What is Protagenic Therapeutics, Inc. stock quote today ?

Protagenic Therapeutics, Inc. stock price is $1.82 today.

Is Protagenic Therapeutics, Inc. stock public?

Yes, Protagenic Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap